Gyre Therapeutics (GYRE) Interest & Investment Income (2010 - 2023)
Gyre Therapeutics (GYRE) reported Interest & Investment Income of $47000.0 for Q3 2023, down 83.33% year-over-year from $282000.0 in Q3 2022, and down 35.62% quarter-over-quarter from $73000.0 in Q2 2023.
Gyre Therapeutics (GYRE) Interest & Investment Income (2010 - 2023) Analysis & Trends
Gyre Therapeutics (GYRE) has 14 years of Interest & Investment Income data on file, last reported at $47000.0 in Q3 2023.
- Interest & Investment Income for Q3 2023 came in at $47000.0, down 83.33% year-over-year; the trailing twelve-month figure through Sep 2023 was $384000.0 (down 30.56% YoY), and the FY2022 annual result was $717000.0, up 1738.46% from the prior year.
- Interest & Investment Income declined to $47000.0 in Q3 2023 per GYRE's latest filing, from $73000.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $631000.0 in Q1 2019 and troughed at -$634000.0 in Q4 2020.
- A 5-year average of $158052.6 and a median of $102000.0 in 2022 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2020 and 2022: Interest & Investment Income tumbled 249.88% in 2020, then surged 4100.0% in 2022.
- A 5-year view of Interest & Investment Income shows it stood at $423000.0 in 2019, then plunged by 249.88% to -$634000.0 in 2020, then surged by 100.63% to $4000.0 in 2021, then surged by 4100.0% to $168000.0 in 2022, then tumbled by 72.02% to $47000.0 in 2023.
- Business Quant data shows GYRE's Interest & Investment Income at $47000.0 in Q3 2023, $73000.0 in Q2 2023, and $96000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 597,319.59 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 305,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -14.79 Mn |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 47,000.00 |
| Jun 30, 2023 | 73,000.00 |
| Mar 31, 2023 | 96,000.00 |
| Dec 31, 2022 | 168,000.00 |
| Sep 30, 2022 | 282,000.00 |
| Jun 30, 2022 | 102,000.00 |
| Mar 31, 2022 | 165,000.00 |
| Dec 31, 2021 | 4,000.00 |
| Sep 30, 2021 | 7,000.00 |
| Jun 30, 2021 | 11,000.00 |
| Mar 31, 2021 | 17,000.00 |
| Dec 31, 2020 | -634,000.00 |
| Sep 30, 2020 | 74,000.00 |
| Jun 30, 2020 | 113,000.00 |
| Mar 31, 2020 | 334,000.00 |
| Dec 31, 2019 | 423,000.00 |
| Sep 30, 2019 | 489,000.00 |
| Jun 30, 2019 | 601,000.00 |
| Mar 31, 2019 | 631,000.00 |
| Dec 31, 2018 | -1.54 Mn |